Core Viewpoint - Peijia Medical reported strong financial results for the first half of 2025, showcasing revenue growth, improved profitability, and significant advancements in its product pipeline, particularly in the transcatheter valve therapeutics and neurovascular interventions markets [1][14]. Financial Performance - Revenue for the six months ended June 30, 2025, reached RMB353.4 million, representing a 17.3% increase compared to the previous period [2]. - The revenue composition remained stable, with TAVR-related products contributing 45.7% and neurointerventional products 54.3% [2]. - TAVR-related product revenue increased by 24.0% to RMB161.6 million, driven by market share gains and a favorable product mix [3]. - Neurointerventional product revenue grew by 12.2% to RMB191.8 million, supported by deeper market penetration and the successful launch of the YonFlow® Flow Diverting Stent [3]. Operational Efficiency - The Group improved operational performance, with the Neurointerventional Business segment profit increasing by 42.4% to RMB40.9 million, while the loss in the Transcatheter Valve Therapeutic Business narrowed by 35.3% to RMB76.1 million [4]. - Selling and distribution expenses for the segment decreased by 8.3% to RMB100.0 million, with the selling and distribution expense ratio dropping by 21.8 percentage points to 61.9% [7]. - R&D expenses decreased by 17.2% to RMB54.2 million, attributed to the completion of major pivotal trials [8]. Product Development and Pipeline - The Group expanded its TAVR product hospital coverage by over 70, reaching more than 720 medical institutions in China, with total terminal implant volume exceeding 2,050 units, an 18.8% increase [5]. - Three core pipeline products are nearing registration, with the NMPA accepting the registration application for TaurusTrio™ in April 2025, and applications for TaurusNXT® and GeminiOne® expected soon [9]. - The Neurointerventional Business continued to perform strongly, with sales of the DCwire® Micro Guidewire surging nearly 140% period-to-period [11]. Market Position and Future Outlook - The Group's comprehensive product portfolio includes upgraded TAVR products, maintaining stable average ex-factory prices and margins while expanding market accessibility [6]. - The company is well-positioned for sustained future growth, with a commitment to innovation and operational excellence, as highlighted by the Chairman and CEO [14][15].

Core Viewpoint - Peijia Medical Limited reported a total revenue of RMB 353 million for the six months ending June 30, 2025, representing a 17.3% increase compared to the same period in 2024, with stable revenue contributions from TAVR and neurointerventional products [1] Financial Summary - The sales revenue from TAVR-related products increased by 24.0% to RMB 162 million, driven by an enhanced market share in China's TAVR market and a shift towards newly launched high-end products [2] - Neurointerventional products saw a 12.2% increase in sales revenue to RMB 192 million, supported by deeper market penetration of existing products and the successful launch of the YonFlow® stent [2] - The overall operating loss narrowed by 19.4% to RMB 68.32 million, with core business net loss significantly reduced by 52.4% to RMB 30.72 million [2] Cost Control and Efficiency - The TAVR business achieved commercial profitability for the first time, generating a profit of RMB 29.09 million, with sales and distribution expenses decreasing by 8.3% to RMB 100 million [4] - R&D expenses for the TAVR division decreased by 17.2% to RMB 54.2 million, primarily due to the completion of major clinical trials [4] - The management expenses slightly increased by 2.8% to RMB 50.98 million, mainly due to depreciation costs of a new headquarters [4] Innovation and Product Development - Three key in-development products are entering the registration application phase, including the TaurusTrio™ TAVR system, TaurusNXT® TAVR system, and GeminiOne® TEER system, with expected approvals between late 2025 and mid-2026 [5] - The DCwire® microguidewire and YonFlow® stent are highlighted as strong performers in the neurointerventional segment, with the former's sales revenue increasing nearly 140% [9] - The company is preparing for the market launch of the TaurusTrio™, which is expected to significantly enhance its competitive position in the AR valve market [5] Operational Efficiency - The neurointerventional division's profit increased by 42.4% to RMB 40.9 million, supported by effective cost control and operational efficiency measures [11] - The company has successfully integrated lean production and supply chain management to mitigate revenue pressures from centralized procurement [11] - The overall strategy emphasizes innovation-driven growth, operational efficiency, and maintaining market leadership in cardiovascular disease treatments [11]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Peijia Medical Limited 沛嘉醫療有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9996） 自願公告 2025年1月1日至2025年6月30日期間 的未經審核營運數據 本公告由沛嘉醫療有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 刊發，以向本公司股東及潛在投資者提供有關本集團最新業務及產品開發進 展的最新資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本集團截至2025年6月30日止六 個月（「報告期間」）的若干未經審核營運數據及比較數字列如下。 1月1日至6月30日期間 | 2025年 | 2024年 | 變動 | | --- | --- | --- | | 人民幣百萬元 | 人民幣百萬元 | % | 收入 約350.0–360.0 301.2 約16.2–19.5 本集團收入增長持續的主要驅動因素如下： (i) 我 ...